Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN NASDAQ:PLRX NASDAQ:PRLD NASDAQ:TARA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$14.48+1.7%$14.70$9.44▼$20.90$301.50M0.8181,704 shs48,053 shsPLRXPliant Therapeutics$1.21+1.3%$1.29$1.09▼$1.95$74.61M1.2696,947 shs217,759 shsPRLDPrelude Therapeutics$4.84+2.0%$3.65$0.73▼$5.54$304.05M1.11394,067 shs269,247 shsTARAProtara Therapeutics$5.41-0.8%$5.43$2.77▼$7.82$297.66M1.53979,974 shs359,036 shs7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin0.00%+1.01%-4.55%-6.51%+28.96%PLRXPliant Therapeutics0.00%-0.83%-11.11%-0.83%-28.99%PRLDPrelude Therapeutics0.00%+3.98%+35.84%+105.24%+429.64%TARAProtara Therapeutics0.00%+6.61%+4.11%-21.19%+48.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$14.48+1.7%$14.70$9.44▼$20.90$301.50M0.8181,704 shs48,053 shsPLRXPliant Therapeutics$1.21+1.3%$1.29$1.09▼$1.95$74.61M1.2696,947 shs217,759 shsPRLDPrelude Therapeutics$4.84+2.0%$3.65$0.73▼$5.54$304.05M1.11394,067 shs269,247 shsTARAProtara Therapeutics$5.41-0.8%$5.43$2.77▼$7.82$297.66M1.53979,974 shs359,036 shs7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin0.00%+1.01%-4.55%-6.51%+28.96%PLRXPliant Therapeutics0.00%-0.83%-11.11%-0.83%-28.99%PRLDPrelude Therapeutics0.00%+3.98%+35.84%+105.24%+429.64%TARAProtara Therapeutics0.00%+6.61%+4.11%-21.19%+48.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 2.00Hold$12.00-17.24% DownsidePLRXPliant Therapeutics 1.80Reduce$3.00151.05% UpsidePRLDPrelude Therapeutics 2.40Hold$7.6757.85% UpsideTARAProtara Therapeutics 2.83Moderate Buy$24.75357.06% UpsideCurrent Analyst Ratings BreakdownLatest PLRX, PRLD, TARA, and AMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026PRLDPrelude Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.005/1/2026PRLDPrelude Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026TARAProtara Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$23.00 ➝ $27.004/28/2026PRLDPrelude Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/27/2026PRLDPrelude Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $8.004/21/2026PLRXPliant Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026TARAProtara Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026AMRNAmarin Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/2/2026AMRNAmarin Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/13/2026PLRXPliant Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$4.00 ➝ $3.003/12/2026PLRXPliant Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$4.00 ➝ $3.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$213.65M1.41$0.37 per share38.98$22.07 per share0.66PLRXPliant Therapeutics$1.58M46.83N/AN/A$2.95 per share0.41PRLDPrelude Therapeutics$12.14M25.21N/AN/A$1.09 per share4.46TARAProtara TherapeuticsN/AN/AN/AN/A$3.80 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$38.80M-$0.65N/AN/AN/A-15.51%-2.99%-2.07%N/APLRXPliant Therapeutics-$149.34M-$2.44N/AN/AN/AN/A-68.71%-51.47%5/14/2026 (Estimated)PRLDPrelude Therapeutics-$99.50M-$1.29N/AN/AN/AN/A-129.98%-80.85%5/5/2026 (Estimated)TARAProtara Therapeutics-$57.44M-$1.32N/AN/AN/AN/A-36.38%-33.81%5/14/2026 (Estimated)Latest PLRX, PRLD, TARA, and AMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026PLRXPliant Therapeutics-$0.36N/AN/AN/AN/AN/A5/14/2026Q1 2026TARAProtara Therapeutics-$0.36N/AN/AN/AN/AN/A5/5/2026Q1 2026PRLDPrelude Therapeutics-$0.27N/AN/AN/A$5.88 millionN/A3/11/2026Q4 2025PLRXPliant Therapeutics-$0.44-$0.35+$0.09-$0.38N/AN/A3/10/2026Q4 2025PRLDPrelude Therapeutics-$0.33-$0.20+$0.13-$0.20$20.50 million$5.64 million3/10/2026Q4 2025TARAProtara Therapeutics-$0.34-$0.37-$0.03-$0.37N/AN/A2/25/2026Q4 2025AMRNAmarin-$1.27$0.01+$1.28N/A$50.62 million$49.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.482.46PLRXPliant TherapeuticsN/A12.0012.00PRLDPrelude TherapeuticsN/A1.991.99TARAProtara TherapeuticsN/A14.5814.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%PLRXPliant Therapeutics97.30%PRLDPrelude Therapeutics79.72%TARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipAMRNAmarin4.21%PLRXPliant Therapeutics6.40%PRLDPrelude Therapeutics63.90%TARAProtara Therapeutics12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.80 million19.93 millionOptionablePLRXPliant Therapeutics9061.92 million57.95 millionOptionablePRLDPrelude Therapeutics12063.00 million22.74 millionOptionableTARAProtara Therapeutics3055.06 million48.18 millionOptionablePLRX, PRLD, TARA, and AMRN HeadlinesRecent News About These CompaniesOne Protara Therapeutics Insider Raised Their Stake In The Previous YearMay 4 at 8:39 AM | finance.yahoo.comEquities Analysts Offer Predictions for TARA FY2028 EarningsMay 4 at 1:33 AM | marketbeat.comProtara Therapeutics (NASDAQ:TARA) Price Target Raised to $27.00 at HC WainwrightApril 29, 2026 | marketbeat.comProtara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association ...April 28, 2026 | markets.businessinsider.comProtara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual MeetingApril 27, 2026 | globenewswire.comProtara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from BrokeragesApril 26, 2026 | marketbeat.comStock Traders Buy Large Volume of Protara Therapeutics Call Options (NASDAQ:TARA)April 8, 2026 | marketbeat.comJacqueline Zummo Sells 22,598 Shares of Protara Therapeutics (NASDAQ:TARA) StockApril 3, 2026 | insidertrades.comProtara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdateMarch 10, 2026 | globenewswire.comBladder phase II sinks Protara, LMs phase III wins for PalvellaFebruary 25, 2026 | bioworld.comBProtara reports encouraging phase 2 results for TARA-002 in bladder cancer studyFebruary 25, 2026 | msn.comTARA-002 results send Protara shares upwardsFebruary 24, 2026 | thepharmaletter.comTProtara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 monthsFebruary 24, 2026 | fiercebiotech.comFProtara's experimental bladder cancer drug shows encouraging resultsFebruary 24, 2026 | msn.comProtara falls after mid-stage trial data for lead asset in bladder cancerFebruary 24, 2026 | msn.comProtara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer TranscriptFebruary 24, 2026 | seekingalpha.comProtara Therapeutics Shares Surge on Promising Clinical Trial DataFebruary 24, 2026 | aktiencheck.deADoes TARA stock’s 15% after-hours slump signal a bargain after new bladder cancer data?February 24, 2026 | msn.comProtara Therapeutics stock tumbles on trial data releaseFebruary 23, 2026 | za.investing.comTARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder CancerFebruary 23, 2026 | globenewswire.comProtara Therapeutics to Participate in Upcoming Investor ConferencesFebruary 19, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePLRX, PRLD, TARA, and AMRN Company DescriptionsAmarin NASDAQ:AMRN$14.48 +0.24 (+1.67%) As of 03:51 PM Eastern This is a fair market value price provided by Massive. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Pliant Therapeutics NASDAQ:PLRX$1.20 +0.02 (+1.26%) As of 03:51 PM Eastern This is a fair market value price provided by Massive. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.Prelude Therapeutics NASDAQ:PRLD$4.84 +0.10 (+2.00%) As of 03:51 PM Eastern This is a fair market value price provided by Massive. Learn more.Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.Protara Therapeutics NASDAQ:TARA$5.40 -0.05 (-0.83%) As of 03:51 PM Eastern This is a fair market value price provided by Massive. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
